MA32945B1 - Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique - Google Patents
Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutiqueInfo
- Publication number
- MA32945B1 MA32945B1 MA33989A MA33989A MA32945B1 MA 32945 B1 MA32945 B1 MA 32945B1 MA 33989 A MA33989 A MA 33989A MA 33989 A MA33989 A MA 33989A MA 32945 B1 MA32945 B1 MA 32945B1
- Authority
- MA
- Morocco
- Prior art keywords
- substituted
- preparation
- treatment
- tetrahydroperan
- biperidenone
- Prior art date
Links
- 150000003857 carboxamides Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003607 modifier Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION ET CONCERNE UNE SÉRIE DE CARBOXAMIDES DE N-PHÉNYL-BIPYRROLIDINE DE FORMULE (I) DANS LAQUELLE: R1, R2, M, N ET P SONT TELS QUE DÉFINIS DANS LA DESCRIPTION. D'UNE MANIÈRE PLUS SPÉCIFIQUE, LES COMPOSÉS SELON L'INVENTION SONT DES MODULATEURS DES RÉCEPTEURS H3 ET SONT DONC UTILES EN TANT QU'AGENT PHARMACEUTIQUES, NOTAMMENT DANS LE TRAITEMENT ET/OU LA PRÉVENTION DE DIVERSES MALADIES MODULÉES PAR LES RÉCEPTEURS H3 COMPRENANT LES MALADIES ASSOCIÉES AU SYSTÈME CENTRAL NERVEUX. EN OUTRE, LA PRÉSENTE INVENTION CONCERNE ÉGALEMENT DES PROCÉDÉS DE PRÉPARATION DE CARBOXAMIDES DE N-PHÉNYL-BIPYRROLIDINE SUBSTITUÉS ET DES INTERMÉDIAIRES UTILISÉS À CET EFFET.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12008708P | 2008-12-05 | 2008-12-05 | |
| FR0955909 | 2009-08-28 | ||
| PCT/US2009/066666 WO2010065798A1 (fr) | 2008-12-05 | 2009-12-04 | Pyrrolidinone et pipéridinone spiro à substitution de tétrahydropyranne, sa preparation et son utilisation thérapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32945B1 true MA32945B1 (fr) | 2012-01-02 |
Family
ID=41665099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33989A MA32945B1 (fr) | 2008-12-05 | 2009-12-04 | Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US8217052B2 (fr) |
| EP (1) | EP2373659B1 (fr) |
| JP (1) | JP5410544B2 (fr) |
| KR (1) | KR101682889B1 (fr) |
| CN (1) | CN102239170B (fr) |
| AR (1) | AR074467A1 (fr) |
| AU (1) | AU2009322243B2 (fr) |
| CA (1) | CA2745715C (fr) |
| CO (1) | CO6390059A2 (fr) |
| CR (1) | CR20110289A (fr) |
| DO (1) | DOP2011000166A (fr) |
| EC (1) | ECSP11011109A (fr) |
| ES (1) | ES2507574T3 (fr) |
| HN (1) | HN2011001487A (fr) |
| IL (1) | IL213292A (fr) |
| MA (1) | MA32945B1 (fr) |
| MX (1) | MX2011004791A (fr) |
| MY (1) | MY150789A (fr) |
| NZ (1) | NZ593150A (fr) |
| PA (1) | PA8852301A1 (fr) |
| PE (1) | PE20110773A1 (fr) |
| RU (1) | RU2519778C2 (fr) |
| TN (1) | TN2011000223A1 (fr) |
| TW (1) | TWI441826B (fr) |
| UA (1) | UA104880C2 (fr) |
| WO (1) | WO2010065798A1 (fr) |
| ZA (1) | ZA201103261B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR074466A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. |
| AR081384A1 (es) * | 2010-05-11 | 2012-08-29 | Sanofi Aventis | N- fenil espirolactama bipirrolidinas sustituidas, preparacion y uso terapeutico de las mismas |
| WO2011143145A1 (fr) | 2010-05-11 | 2011-11-17 | Sanofi | Dérivés n-alkyl et n-acyl tétrahydro-isoquinoline substitués, procédé de préparation et application thérapeutiques associés |
| JP5968307B2 (ja) | 2010-05-11 | 2016-08-10 | サノフイ | 置換フェニルシクロアルキルピロリジン（ピペリジン）スピロラクタム類及びアミド類、それらの製造及び治療的使用 |
| JP2013529198A (ja) | 2010-05-11 | 2013-07-18 | サノフイ | 置換されたｎ−ヘテロシクロアルキルビピロリジニルフェニルアミド誘導体、その製造及び治療上の使用 |
| TW201202251A (en) * | 2010-05-11 | 2012-01-16 | Sanofi Aventis | Substituted N-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
| JP2013526529A (ja) | 2010-05-11 | 2013-06-24 | サノフイ | 置換されたｎ−ヘテロアリールビピロリジンカルボキサミド、その製造及び治療上の使用 |
| JP5784110B2 (ja) | 2010-05-11 | 2015-09-24 | サノフイ | 置換されたｎ−ヘテロアリールテトラヒドロ−イソキノリン誘導体、その製造及び治療上の使用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3256276A (en) * | 1961-02-17 | 1966-06-14 | Geschickter Fund Med Res | Substituted spiroimides |
| US3258276A (en) | 1964-04-06 | 1966-06-28 | Charles E Murcott | Utility chair |
| WO2003031432A1 (fr) * | 2001-10-12 | 2003-04-17 | Novo Nordisk A/S | Nouvelles piperidines substituees |
| US6889262B1 (en) | 2002-06-26 | 2005-05-03 | Advanced Micro Devices, Inc. | Direct transaction mode for peripheral devices |
| WO2004037257A1 (fr) * | 2002-10-23 | 2004-05-06 | Janssen Pharmaceutica, N.V. | Phenylpiperidines et phenylpyrrolidines utilisees comme modulateurs du recepteur h3 de l'histamine |
| US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| CA2551037A1 (fr) * | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de piperidine |
| ATE523488T1 (de) * | 2005-07-01 | 2011-09-15 | Lilly Co Eli | Histamin-h3-rezeptor-mittel, deren herstellung und therapeutische verwendung |
| BRPI0618354B8 (pt) * | 2005-11-10 | 2021-05-25 | Banyu Pharma Co Ltd | composto e seu uso, composição farmacêutica, preventivo ou remédio |
| JP2009519293A (ja) | 2005-12-16 | 2009-05-14 | エフ．ホフマン−ラ ロシュ アーゲー | Ｈ３レセプター調節剤としてのピロロ［２，３−ｂ］ピリジン誘導体 |
| US20080247964A1 (en) * | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
| US8318927B2 (en) * | 2006-05-23 | 2012-11-27 | High Point Pharmaceuticals, Llc | 6-(4-cyclopropylpiperazin-1-yl)-2′-methyl-[3, 4′]-bipyridine and its uses as a medicament |
| JP2009544579A (ja) | 2006-06-29 | 2009-12-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 置換ベンジルアミン化合物 |
| WO2009039431A2 (fr) | 2007-09-21 | 2009-03-26 | Neurogen Corporation | Amines spirocycliques aryl-condensées substituées |
| BRPI0818581A2 (pt) | 2007-10-17 | 2015-07-21 | Sanofi Aventis | Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas |
| DK2212282T3 (da) | 2007-10-17 | 2012-01-23 | Sanofi Sa | Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf |
| KR20100092443A (ko) | 2007-10-17 | 2010-08-20 | 사노피-아벤티스 | 치환된 ｎ-페닐-피롤리디닐메틸피롤리딘 아미드 및 히스타민 ｈ3 수용체 조절제로서의 이의 치료적 용도 |
| AR074466A1 (es) | 2008-12-05 | 2011-01-19 | Sanofi Aventis | Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3. |
-
2009
- 2009-12-03 AR ARP090104667A patent/AR074467A1/es unknown
- 2009-12-04 NZ NZ593150A patent/NZ593150A/xx not_active IP Right Cessation
- 2009-12-04 EP EP09775421.2A patent/EP2373659B1/fr active Active
- 2009-12-04 PE PE2011001127A patent/PE20110773A1/es not_active Application Discontinuation
- 2009-12-04 CN CN200980148490.7A patent/CN102239170B/zh active Active
- 2009-12-04 MY MYPI20112068 patent/MY150789A/en unknown
- 2009-12-04 CA CA2745715A patent/CA2745715C/fr not_active Expired - Fee Related
- 2009-12-04 UA UAA201108412A patent/UA104880C2/uk unknown
- 2009-12-04 AU AU2009322243A patent/AU2009322243B2/en not_active Ceased
- 2009-12-04 JP JP2011539715A patent/JP5410544B2/ja active Active
- 2009-12-04 MX MX2011004791A patent/MX2011004791A/es active IP Right Grant
- 2009-12-04 ES ES09775421.2T patent/ES2507574T3/es active Active
- 2009-12-04 WO PCT/US2009/066666 patent/WO2010065798A1/fr not_active Ceased
- 2009-12-04 PA PA20098852301A patent/PA8852301A1/es unknown
- 2009-12-04 RU RU2011127382/04A patent/RU2519778C2/ru not_active IP Right Cessation
- 2009-12-04 KR KR1020117014404A patent/KR101682889B1/ko not_active Expired - Fee Related
- 2009-12-04 MA MA33989A patent/MA32945B1/fr unknown
- 2009-12-04 TW TW098141444A patent/TWI441826B/zh not_active IP Right Cessation
-
2011
- 2011-05-05 ZA ZA2011/03261A patent/ZA201103261B/en unknown
- 2011-05-06 TN TN2011000223A patent/TN2011000223A1/fr unknown
- 2011-05-27 CR CR20110289A patent/CR20110289A/es unknown
- 2011-05-31 IL IL213292A patent/IL213292A/en not_active IP Right Cessation
- 2011-06-01 DO DO2011000166A patent/DOP2011000166A/es unknown
- 2011-06-02 US US13/151,925 patent/US8217052B2/en active Active
- 2011-06-02 CO CO11068492A patent/CO6390059A2/es active IP Right Grant
- 2011-06-03 HN HN2011001487A patent/HN2011001487A/es unknown
- 2011-06-03 EC EC2011011109A patent/ECSP11011109A/es unknown
-
2012
- 2012-05-30 US US13/483,503 patent/US8383814B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
| EA201071169A1 (ru) | ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3 | |
| MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique | |
| EA201001647A1 (ru) | Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов | |
| ECSP10010582A (es) | Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
| EA201190235A1 (ru) | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 | |
| CY1116791T1 (el) | 4-αρυλ-ν-φαινυλ-1,3,5-τριαζιν-αμινες που περιεχουν μια ομαδα σουλφοξιμινης | |
| EA201100299A1 (ru) | Органические соединения | |
| EA201270575A1 (ru) | Соединения | |
| EA201170772A1 (ru) | Органические соединения | |
| MA32811B1 (fr) | Nouveaux composés | |
| EA200970967A1 (ru) | Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip) | |
| EA201500953A1 (ru) | 3-ацетиламино-1-(фенилгетероариламинокарбонил или фенилгетероарилкарбониламино)бензольные производные для лечения гиперпролиферативных нарушений | |
| EA201391720A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
| EA201491028A1 (ru) | Способ получения замещенных 5-фтор-1н-пиразолопиридинов | |
| EA201170356A1 (ru) | Полиморфные и аморфные формы лакозамида и аморфные композиции | |
| MA32945B1 (fr) | Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique | |
| MA32723B1 (fr) | Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments | |
| EA201190293A1 (ru) | Пролекарства триптолида | |
| EA200970583A1 (ru) | Способ получения пиперазиниловых и диазепаниловых производных бензамида | |
| EA200970065A1 (ru) | Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38 | |
| MA32505B1 (fr) | 5-alcynyl-pyrimidines |